Issued Patents All Time
Showing 1–25 of 27 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 12403178 | Use of CD33CAR modified high affinity NK cells (t-haNK) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on NK cell activity) | Patrick Soon-Shiong, Hans G. Klingemann, Himani Chinnapen, Abhijit Dandapat | 2025-09-02 |
| 12384852 | Genetically modified NK-92 cells having a safety switch | Tien Lee, Hans G. Klingemann, Barry J. Simon, Kerry S. Campbell | 2025-08-12 |
| 12378300 | Elimination of CD19-positive lymphoid malignancies by CD19-car expressing NK cells | Hans G. Klingemann, Patrick Soon-Shiong | 2025-08-05 |
| 12365874 | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors | John H. Lee, Hans G. Klingemann | 2025-07-22 |
| 12180283 | Anti-B7-H4 chimeric antigen receptor-modified NK-92 cells | Hans G. Klingemann | 2024-12-31 |
| 12109238 | Chimeric antigen receptor-modified NK-92 cells | Hans G. Klingemann | 2024-10-08 |
| 11992504 | Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment | John H. Lee, Hans G. Klingemann | 2024-05-28 |
| 11813292 | Use of CD33CAR modified high affinity NK cells (t-haNK) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on NK cell activity) | Patrick Soon-Shiong, Hans G. Klingemann, Himani Chinnapen, Abhijit Dandapat | 2023-11-14 |
| 11753625 | Modified NK-92 haNK003 cells for the clinic | Hans G. Klingemann, Patrick Soon-Shiong | 2023-09-12 |
| 11643452 | Fc-epsilon car | Hans G. Klingemann, Abhijit Dandapat, Himani Chinnapen | 2023-05-09 |
| 11547727 | Chimeric antigen receptor-modified NK-92 cells | Hans G. Klingemann | 2023-01-10 |
| 11439697 | Nant cancer vaccine | Patrick Soon-Shiong, Kayvan Niazi, Shahrooz Rabizadeh, Hans G. Klingemann, Barry J. Simon | 2022-09-13 |
| 11230699 | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors | John H. Lee, Hans G. Klingemann | 2022-01-25 |
| 11221328 | Hypoxic NK cells and methods therefor | Patrick Soon-Shiong, Shahrooz Rabizadeh, Kayvan Niazi, Stephen Charles Benz, Hans G. Klingemann +1 more | 2022-01-11 |
| 11207392 | Coordinated multi-prong cancer therapy | Patrick Soon-Shiong, Kayvan Niazi, Shahrooz Rabizadeh, Hans G. Klingemann, Barry J. Simon | 2021-12-28 |
| 11207350 | Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer | Tien Lee, Hans G. Klingemann, Barry J. Simon | 2021-12-28 |
| 11129850 | Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies | Hans G. Klingemann, Nathan T. Schomer | 2021-09-28 |
| 11077143 | Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cells | Hans G. Klingemann, Abhijit Dandapat | 2021-08-03 |
| 11071774 | Nant cancer vaccine | Patrick Soon-Shiong, Kayvan Niazi, Shahrooz Rabizadeh, Hans G. Klingemann | 2021-07-27 |
| 11058723 | Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies | Hans G. Klingemann, Nathan T. Schomer | 2021-07-13 |
| 11000550 | Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer | Tien Lee, Hans G. Klingemann, Barry J. Simon | 2021-05-11 |
| 10960024 | Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies | Hans G. Klingemann, John H. Lee, Nathan T. Schomer | 2021-03-30 |
| 10801013 | Modified NK-92 haNK003 cells for the clinic | Hans G. Klingemann, Patrick Soon-Shiong | 2020-10-13 |
| 10774310 | Modified NK-92 haNK003 cells for the clinic | Hans G. Klingemann, Patrick Soon-Shiong | 2020-09-15 |
| 10765701 | Elimination of CD19-positive lymphoid malignancies by CD19-CAR expressing NK cells | Hans G. Klingemann, Patrick Soon-Shiong | 2020-09-08 |